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3-Methylcrotonylglycinuria is an inborn error of leucine catabolism and has a recessive pattern of inheritance that
results from the deficiency of 3-methylcrotonyl-CoA carboxylase (MCC). The introduction of tandem mass spec-
trometry in newborn screening has revealed an unexpectedly high incidence of this disorder, which, in certain areas,
appears to be the most frequent organic aciduria. MCC, an heteromeric enzyme consisting of a (biotin-containing)
and b subunits, is the only one of the four biotin-dependent carboxylases known in humans that has genes that
have not yet been characterized, precluding molecular studies of this disease. Here we report the characterization,
at the genomic level and at the cDNA level, of both the MCCA gene and the MCCB gene, encoding the MCCa
and MCCb subunits, respectively. The 19-exon MCCA gene maps to 3q25-27 and encodes a 725-residue protein
with a biotin attachment site; the 17-exon MCCB gene maps to 5q12-q13 and encodes a 563-residue polypeptide.
We show that disease-causing mutations can be classified into two complementation groups, denoted “CGA” and
“CGB.” We detected twoMCCAmissense mutations in CGA patients, one of which leads to absence of biotinylated
MCCa. Two MCCB missense mutations and one splicing defect mutation leading to early MCCb truncation were
found in CGB patients. A fourth MCCB mutation also leading to early MCCb truncation was found in two
nonclassified patients. A fungal model carrying an mccA null allele has been constructed and was used to dem-
onstrate, in vivo, the involvement of MCC in leucine catabolism. These results establish that 3-methylcrotonylgly-
cinuria results from loss-of-function mutations in the genes encoding the a and b subunits of MCC and complete
the genetic characterization of the four human biotin-dependent carboxylases.
Introduction
3-Methylcrotonylglycinuria (MCG [MIM 210200]) is
an inborn error of leucine catabolism and results from
isolated, biotin-insensitive deficiency of 3-methylcro-
tonyl-CoA carboxylase (MCC; E.C.6.4.1.4), the enzyme
converting 3-methylcrotonoyl-CoA to 3-methylgluta-
conyl-CoA (Sweetman and Williams 1995). This mito-
chondrial enzyme is one of the four biotin-dependent
carboxylases known in humans (Wolf 1995), together
with acetyl CoA carboxylase (ACC), pyruvate carbox-
ylase (PC), and propionyl CoA carboxylase (PCC). In
marked similarity to PCC, MCC is a hetero-oligomeric
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enzyme consisting of a and b subunits. Both PCCa and
MCCa contain a covalently bound biotin moiety, as well
as binding sites for two of the substrates, HCO3
 and
ATP, whereas the b subunits contain the binding site for
the acyl-CoA substrate (Lau et al. 1980; Lamhonwah et
al. 1986; Song et al. 1994; Sweetman and Williams
1995).
Patients with MCG, which is inherited as an auto-
somal recessive trait, show a highly variable clinical
phenotype, ranging from asymptomatic to severe. In the
latter phenotype, episodes of acute metabolic decom-
pensation can lead to coma, lethargy, and death (Sweet-
man and Williams 1995). The metabolic phenotype
characterizing MCC deficiency is the elevated excre-
tion of the diagnostic compounds 3-methylcrotonylgly-
cine or 3-hydroxyisovaleric acid and the presence of
abnormally elevated blood or urine levels of 3-hydrox-
yisovalerylcarnitine (C5-OH), as determined by tandem
mass spectrometry (MS/MS) (van Hove et al. 1995; Gib-
son et al. 1998). The recent introduction of neonatal
screening of organic acidurias by MS/MS has revealed
Gallardo et al.: 3-Methylcrotonyl-CoA Carboxylase Deficiency 335
Table 1
Primers for Amplification of MCCA and MCCB Sequences
FORWARD PRIMER
(5 ′r3′)
REVERSE PRIMER
(5 ′r3′) AMPLIFIED TARGET
PCR-FRAGMENT SIZE
(bp)
MCCA
TGGAATTTCTAGTAAGGCAAGCa AAGTTGTGTTTCTCTTGCCTTCa Exon 9 219
ACCATTGAATGAAGACAGCGGb GTGCTGGGACTACAGGCTTGb Exon 10 306
CATAAGAAACACTATTCTATTGCCb AATATGCTAGACAGTTCTGTAAGb Exon 11 316
AATCAGACAAAAGGGAATCGGa TAATTAGTGACCCAAATGCATGa Exon 19 194
MCCB
GCTATATTTTGGATTAAGTATTATGc TACAAGACTGTCTAATAAAGTACc Exon 3 245
ATCTCTTAAATTCTCTCTCAATGc CAAACTATTTGCATTTTACCAGCc Exon 5 226
GCTGTCATTGATACAAGTTTCCc CATCCCAGAGTACCTAATTCGc Exon 6 269
CTATAGAAGTCACTGCATGAGCTGc TGTTCTGCATATTTAATTTCATCGc Exon 7 219
GAAAATTAACACATGTAGTAGCCa TATATTAATCATCTCAATAATACAGa Exon 17 300
AGGCAGCCAATGTGTTGGCd CTTTATTAGGAAAACATTTGATAGd 3′ UTR 2,100
a Used only in RH mapping.
b Used both in mutation screening and/or SSCP analysis with human genomic DNA as template and in RH mapping.
c Used only in mutation screening and/or SSCP analysis with human genomic DNA as template.
d Used to amplify the alternative long 3′ UTR of the MCCB gene; the template here was human liver cDNA.
MCG as an unexpectedly frequent disorder (Naylor and
Chace 1999; Ranieri et al. 2000a; Roscher et al. 2000;
Smith et al. 2000; Wilcken et al. 2000). Despite the
exponentially increasing genomic information availa-
ble, the genes for human MCC subunits have not yet
been characterized, precluding molecular studies of this
disease.
Here we report the cDNA sequence and the structure
of the human MCCA and MCCB genes, encoding the
MCC a and b subunits, respectively. We also report,
for both genes, the identification of mutations leading
to MCG. Finally, we use a fungal model for MCG car-
rying an MCCA null allele, to demonstrate, in vivo, the
specific involvement of MCC in leucine catabolism.
Patients, Material, and Methods
Patients
Seven patients have been included in this study. All
eight probands showed an MCC activity of !10% of
that in the controls, in extracts of lymphoblasts or cul-
tured skin fibroblasts, and showed elevated urinary ex-
cretion of the diagnostic compounds 3-methylcroton-
ylglycine or 3-hydroxyisovaleric acid. Probands 15468
(Spain), 15469 (Argentina), and 15765 (United States)
presented, at !6 mo of age, with a severe episode of
metabolic decompensation with hypoglycemia, hyper-
ammonemia, hypocarnitinemia, and metabolic acidosis.
Proband 15766 (United States) was diagnosed at 4 years
of age. Probands 15626 and 15628 were two clinically
asymptomatic female adults belonging to the Amish/
Mennonite population who came to clinical attention
after their children were suspected to be obligate carriers
(Gibson et al. 1998).
Expressed-Sequence Tags (ESTs), DNA Sequencing, and
Chromosomal Localization of MCCA and MCCB
Human IMAGE ESTs were obtained from Incyte Ge-
nomics. Aspergillus nidulans ESTs were obtained from
the Fungal Genetics Stock Centre. DNA sequencing was
performed with a dye-terminator cycle-sequencing kit
(PE Biosystems) and an ABI PRISM 377 automatic se-
quencer. The MCCA and MCCB genes were mapped by
radiation hybrid (RH) mapping in the Stanford Human
Genome Center G3 panel and the Genebridge 4 (Ra-
diation Hybrid Mapping database) panel (Gyapay et al.
1996; Stewart et al. 1997) (Research Genetics). Primers
are shown in table 1.
FISH Mapping
Metaphase chromosomes from human peripheral
blood lymphocytes were prepared as described elsewhere
(Moorhead et al. 1960). Slides were treated with 2 #
SSC at 37C for 30 min, were dehydrated, were dena-
tured for 2 min at 70C in 70% formamide, 2 # SSC
pH 7, and then were dehydrated again. One microgram
of the human MCCA plasmid artificial chromosome
(PAC) RPCIP-4 615H13 (Resource Center/Primary Da-
tabase RZPD) was labeled, by nick-translation, with
SpectrumGreen-dUTP (Vysis) and was coprecipitated
with 5 mg of human Cot-1 DNA (Vysis). DNA was
resuspended in 50% formamide, 2# SSC, 15% dextran
sulfate, were heat-denatured for 10 min at 70C, and
were hybridized to slides for 24 h at 37C. Slides were
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washed for 5 min in 1# SSC at 60C. Chromosomes
were counterstained with 125 ng of DAPI/ml. Images
were visualized by use of a Nikon Eclipse E400 fluo-
rescence microscope and were analyzed by Smart-
Capture software (Vysis).
Cell Culture, Complementation, and Biotin-Labeling
Assays
Fibroblast and lymphoblast cell lines obtained from
patients were confirmed to be deficient in MCC, which
was assayed in extracts by measurement of the incorpo-
ration of [14C]-HCO3
 into acid-precipitable material, as
described elsewhere (Gibson et al. 2000). Cells were cul-
tured, according to standard procedures, in minimal es-
sential medium (MEM) (Life Technologies) supplement-
ed with 1% glutamine, 10% fetal calf serum, and an-
tibiotics. For complementation experiments, cells from
two different lines were plated together at an equal den-
sity, and cell fusion was induced inMEM (without serum)
in the presence of 50% PEG 4000 for 1 min. Cells were
washed to remove residual polyethylene glycol 4000 and
were cultured for a further 24 h under standard condi-
tions. Then the cells were incubated in MEM with 15%
fetal calf serum and 0.1 mM [1-14C]-isovalerate (10 mCi/
mmol; American Radiolabeled Chemicals). Complemen-
tation was monitored by measurement of the incorpo-
ration of labeled isovalerate into macromolecules. Fibro-
blast cell lines deficient in the leucine degradation–
pathway enzyme isovaleryl-CoA dehydrogenase were
used as positive controls complementing MCC-deficient
cell lines. All assays were done in triplicate, with stan-
dard deviations, which, in all cases, were within 10%
of the mean value. SDS-PAGE analysis of [3H]-biotin
labeled mitochondrial carboxylases was as described
elsewhere (Lamhonwah et al. 1983).
Immunohistochemical Localization of hMCCb in
Mitochondria
A His-tagged (at its N-terminus) hMCCb protein con-
taining residues 33–563 was expressed in BL21 Escher-
ichia coli cells and was purified by Ni2 affinity chro-
matography. The purified protein was used to raise a
mouse polyclonal antiserum. This antiserum detects, in
western blot analysis, a liver protein with the expected
electrophoretic mobility for human MCCb. Cultured hu-
man fibroblasts were fixed with 4% paraformaldehyde,
were treated with 0.5% Triton X-100 (in PBS), and were
incubated, for 1 h at 37C, with mouse anti-MCCb an-
tiserum (diluted 1:100 in 50 mM Tris-HCl pH 7.4, 150
mM NaCl, 0.2% Tween 20, and 3% bovine serum al-
bumin). Anti-mouse biotinylated secondary antibody and
Alexa 488–conjugated streptavidinwere fromDAKOand
Molecular Probes, respectively. Immunostaining was an-
alyzed by means of a confocal imaging system.
Identification of Mutations in Patients with MCG
All mutations reported here were identified at both
the genomic level and the cDNA level. To identify mu-
tations at the mRNA level, reverse transcriptase–PCR
(RT-PCR) was performed with the Thermoscript RT-
PCR System (Life Technologies), with mRNA (1 mg) iso-
lated from fibroblasts of patients and controls. The entire
coding sequence of theMCCA gene and theMCCB gene
was amplified in seven or six overlapping fragments,
respectively, and subsequently was sequenced. For ge-
nomic characterization, exons and flanking intronic se-
quences were PCR-amplified by means of primers de-
signed to be specific to the intronic genomic sequences
(table 1). Both sequencing of PCR-amplified fragments
and SSCP analysis were essentially as described else-
where (Beltra´n Valero de Bernabe´ et al. 1998). To rule
out the possibility that missense mutations are frequent
polymorphisms in North American or Spanish popula-
tions, we built a control sample including 1100 chro-
mosomes, using anonymous donors from Madrid and
New York.
Aspergillus Techniques
A lEMBL4 library was screened with fungal EST can-
didates (Fungal Genetics Stock Center) for genes encod-
ing MCCa or MCCb. The cloned inserts in two partially
overlapping positive clones were used to reconstruct a
14-kb region containing mccA, mccB, and a fungal iso-
valeryl-CoA dehydrogenase gene. Intron positions were
determined by comparison with the cDNA sequence. A
linear fragment containing genomic flanking sequences
upstream (1.04 kb) and downstream (1.35 kb) of the
mccA open reading frame in which the complete mccA
coding region between the initiation and stop codons
had been replaced by an argB allele was used to trans-
form an arginine-requiring methG1 argB2 biA1 strain
to arginine prototrophy. Transformed colonies were pu-
rified in minimal medium lacking arginine and were an-
alyzed by Southern blot analysis using mccA- and argB-
specific probes to select a number of independent
transformants carrying the expected replacement of the
resident mccA gene by the argB allele. All these DmccA
transformants were phenotypically indistinguishable
and were unable to grow on leucine. An argB trans-
formant in which the argB allele had replaced the res-
ident mutant argB2 allele was used as an isogenicmccA
control. Growth tests were performed as described else-
where (Ferna´ndez-Can˜o´n and Pen˜alva 1995a), with each
amino acid used, at 30 mM, as sole carbon source. Plates
were incubated for 5 d at 37C.
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Results
Identification and Characterization of Human MCCA
and MCCB cDNAs
The cDNA sequence of MCCA (GenBank accession
number AF310972 [GenBank Overview]) (fig. 1a), en-
coding human MCCa (hMCCa), was assembled by a
combination of dbEST (Expressed Sequence Tags data-
base) searching and conventional cDNA screening of
cDNA libraries. TBLASTN (BLAST) searches of the hu-
man dbEST database, with the Arabidopsis thaliana
MCCa amino acid sequence (Song et al. 1994) used as
a probe, identified incomplete (at the N-terminal coding
region) uterus (GenBank accession number AA134548
[GenBank Overview]; 1.24 kb, excluding polyA) and ad-
renal carcinoma (AA605162 [GenBank Overview]; 1.74
kb) EST clones. Sequencing of these clones revealed a
predicted protein with a biotin-binding site (Leo´n del Rı´o
and Gravel 1994) whose amino acid sequence differed
from those of PCCa and other biotin-dependent carbox-
ylases. It therefore fulfilled the criteria expected ofMCCa.
The largest clone was used as a [32P]-labeled probe in a
hybridization screening of a human liver cDNA library,
which failed to identify clones carrying the translation
start codon but which yielded sequences extending farther
upstream of codon 218 (the most N-terminal codon in
the probe). A further dbEST search with these sequences
identified a muscle EST (AW410916 [GenBank Over-
view]) that provided the missing 5′ region of the transcript
containing the initiator methionine codon, as predicted
on the basis of multiple-sequence alignment (data not
shown) with Arabidopsis thaliana and Aspergillus nidu-
lans (see below) MCCa polypeptides.
hMCCa contains 725 residues and includes the tetra-
peptide 679-AMKM-682 matching the consensus bind-
ing sequence for the essential biotin cofactor (Leo´n del
Rı´o and Gravel 1994), predicted to be attached, via an
amide bond, to the e-amino group of Lys681 (fig. 1a).
Residues 50–502 of human MCCa show 48% identity
to the biotin-carboxylating polypeptide of Escherichia
coli ACC (Waldrop et al. 1994) and include the sequence
209-GGGGKGMR-216, which is strongly conserved
among biotin-carboxylating enzymes. The crystal struc-
ture of bacterial ACC (Thoden et al. 2000) revealed that
this peptide makes a major contribution to the ATP-
binding pocket. hMCCa shows ∼42% identity to its
fungal homologue (see below) and ∼39% identity to
hPCCa.
A human MCCB cDNA, encoding MCCb, was ini-
tially identified by a search of the dbEST, with the hu-
man PCCb amino acid sequence used as a probe.
TBLASTN searches of human dbEST identified a can-
didate clone (GenBank accession number AA465612
[GenBank Overview]) for MCCB. Although this clone
is not currently available, the translation product of the
deposited sequence identified an Aspergillus nidulans
EST (for MCCB) (accession number n1c10 [Fungal (As-
pergillus nidulans, Aspergillus parasiticus, and Neuro-
spora crassa) Cosmid and cDNA Sequencing]). In a third
TBLASTN search, this fungal amino acid sequence iden-
tified kidney (GenBank accession number AI949422
[GenBank Overview]; 0.7 kb) and uterus (GenBank ac-
cession number AI367183 [GenBank Overview]; 1.25
kb) ESTs, the sequencing of which, combined with RT-
PCR using human liver mRNA, served to assemble a
full-length MCCB cDNA (GenBank accession number
AF310971 [GenBank Overview]).
Human MCCB encodes a 563-residue MCCb poly-
peptide (fig. 1b) showing 59% sequence identity to its
Aspergillus nidulans orthologue (the mccB product; see
below) and 29% identity to human PCCb. During the
course of this work, the Arabidopsis thaliana MCC-B
gene was reported (McKean et al. 2000). Arabidopsis
MCC-B is also 59% identical to hMCCb, which con-
firms the correct identification of the human sequences.
Both MCCa and MCCb contain putative signal pep-
tides, in agreement with their predicted mitochondrial
localization. A polyclonal antiserum raised against His-
tagged MCCb purified from recombinant bacteria was
used to confirm the mitochondrial localization of the
protein in normal human fibroblasts (fig. 1d).
Structure and Chromosomal Localization of the MCCA
and MCCB Genes
The intron-exon organization of the human MCCA
gene was obtained from sequence data, available from the
Human Genome Project, of a bacterial artificial chro-
mosome (BAC) (GenBank accession number AC026920
[GenBank Overview]), and from our sequencing data for
a human PAC clone (RZPDRPCI-4 615H13). Thehuman
MCCA gene is split into 19 exons (fig. 1c and table 2).
RH mapping with the Stanford G3 and Genebridge 4
(GB4) panels was initially used to determine the gene’s
chromosomal location.MCCAwas linked to RHmarkers
mapping to different chromosome 3 locations in either
the G3 (3p11.2-p13) or the GB4 (3q25-27) RH panel.
To solve this contradiction, we used FISH. The analysis
of 125 individual metaphases from two independent ex-
periments unambiguously mapped MCCA to the telo-
meric region in the long arm of chromosome 3 (fig. 2).
We conclude that MCCA maps to 3q25-27 (fig. 2A).
We used three Human Genome Sequence clones
(GenBank accession numbers AC010279, AC026775,
and AC025958 [GenBank Overview]) to determine the
structure of the 17-exon human MCCB gene (fig. 1c and
table 2). The MCCB “AA465612” EST sequence, in-
cluded within these genomic clones, belongs to a UniGene
cluster (H. 167531; STS accession number SGC34463 or
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Figure 1 cDNA nucleotide sequence and intron-exon organization of humanMCCA andMCCB. A and B,Nucleotide sequence ofMCCA
(A) andMCCB (B) cDNAs, with deduced translation sequences. Red arrowheads indicate the position of the introns.C, Intron-exonorganization
of the MCCA gene (top) and the MCCB (bottom) gene. D, MCCb protein localizing in mitochondria. A mouse polyclonal antiserum raised
against histidine-tagged MCCb purified from bacteria was used to reveal the mitochondrial localization of MCCb, in immunohistochemical
localization experiments with cultured fibroblasts.
SHGC-34463 [GeneMap’99]) mapping either to 5q12-
13.1 (reference interval D5S637–D5S1977) in the GB4
map or to 5q12 (reference interval D5S647–D5S637) in
the G3 map. In agreement, our RH experiments using
primers that generate an amplicon in the 3′ UTR of exon
17 (table 1) consistently linked the human MCCB gene
to markers mapping to chromosome 5q12-q13.2, in both
the G3 panel and the GB4 panel.
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Table 2
Structure of Human MCCA and Human MCCB
Exon
Size
(bp) 3′ Splice Exon 5′ Splice Intron
Size
(bp)
MCCA:
1 222 GCCCAAAGGTAG.......CTG CCG CCG AG gtgggtggaggg 1 4,746
2 47 Tttatgttatag G ACA TGG GTG.........ACA GCC ACA G gtactgacagac 2 2,014
3 137 Tgttttaaacag GA AGA AAC ATT......CAT GTA GAT ATG gtatgtgttaaa 3 11,867
4 96 Tttcttaaacag GCA GAT GAA GCA.....TCT GCT GCA CAG gtgagggttgtg 4 114,033
5 122 Tctcatttctag GCT ATC CAT CCA......GGT ATA AAG AG gtatgagtttat 5 1,008
6 148 Cccactctaaag C ACA TCC AAA.......GGA GGA GGA AAA gtaagattgtgc 6 89
7 122 Tttctctcttag GGA ATG AGG ATT......GAC ACA CCG AG gtgggttggcct 7 15,793
8 112 Gcttttatatag G CAT GTA GAA...GAG GCC CCA GCG gtaaggaccttg 8 5,000
9 82 Tttttttcatag CCT GGT ATT AAA.......GTT GGA GCA G gtaggttaagat 9 16,509
10 128 Tttaccttttag GG ACT GTG GAG......TGG CAG CTT AGA gtgagaatattt 10 3,662
11 184 Ttctattgccag ATT GCA GCA GGA.......GTA CGG CAA G gtaaagtgaaag 11 2,431
12 110 Tttcaatttcag GA GAC GAA GTT......CGT CAG TAC AAT gtgagtgatctg 12 1,591
13 21 Ttctcttcctag ATT GTT GGA CTG.......CAG GCA CAT G gtatggaaggct 13 13,054
14 87 Aattttttctag AT CAA TTC TCT........GGT AAA AAC A gtaagtaatgtt 14 111,299
15 50 Ttttccataaag AT GTA GCC ATA......TAT AGC ATG CAG gtaagccttact 15 3,200
16 138 Catttttttcag ATT GAA GAT AAA.....CTA TTT TCC AAG gtaatgtctctt 16 2,179
17 108 Ttctgtttctag GAA GGA AGT ATT.....ACC ATT GAA AAG gtaatcacatga 17 2,792
18 72 Ctgaatctcaag GTG TTT GTC AAA.....ATG AAG ATG GAG gtaaggaaatca 18 1,699
19 347 Gtgtctctgcag CAT ACC ATA AAG....TTTTTATTGGAAGCC
MCCB:
1 237 GGGGCTGCAAGG......GCC CTC TAC CAG gtaggctgagcg 1 5,368
2 67 Tttctgttttag GAG AAC TAC.........ATA AAA CTA G gtaaacacagca 2 3,285
3 85 Tttctatcatag GA GGT GGT.........ATA GAC CCA GG gtgcgtacatag 3 3,290
4 102 Tcttcgctttag G TCT CCA TTT......AGA GTA TCA GG gtgagtatttac 4 2,746
5 128 Tctgcctttcag A GTA GAA TGC.......ATC TAC TTA G gcaagtcaccag 5 1,720
6 113 Tcttgtcttcag TT GAT TCG GGA....AAT ATT GCA CAG gtaatttttcat 6 22,183
7 114 Cttggattccag ATC GCA GTG.......GGA CCC CCC TTG gtaagaacataa 7 5,367
8 65 Tccttgttgtag GTT AAA GCG GCA....CTT CAT TGC AG gtgaaacagaaa 8 2,767
9 100 Cttattctgtag A AAG TCT GGA.....AAG AAA TTG GAT gtgagtacgata 9 108
10 96 Gtatttctgcag GTC ACC ATT GAA...GAT GTC CGA GAG gtatgtgaaagt 10 5,753
11 73 Ttttcctcttag GTC ATT GCT AGA.....TTA GTT ACA G gtataaaggtga 11 2,743
12 77 Ctttcttttgag GA TTT GCT CGA....TCT GCA AAA AAG gcaagtactgtt 12 2,320
13 67 Atttgcttatag GGT ACT CAC TTT.....AAC ATT ACT G gtaagaaaatag 13 2,818
14 157 Tctttctctcag GA TTT ATG GTT.....AGA GCG TAT AG gtaggtgtcatg 14 815
15 115 Ttcttcccccag C CCA AGA TTT.....GAA GGA AAG CAG gtcggtgtcgtt 15 2,485
16 86 Cttttcctttag TTC TCC AGT GCT....TCC AGC GCA AG gtgggggccaga 16 3,987
17 475 Ttcttttgtcag G GTA TGG GAT.....ATTTTCACTGAAATG
Transcription Pattern of the MCCA and MCCB Genes:
Agreement with the Predicted Physiological Role
Unlike most amino acids absorbed across the intestine,
the branched-chain amino acids leucine, valine, and iso-
leucine are not taken up to any great extent by the liver,
which leads to a large increment in their arterial con-
centration after a protein-rich meal (Wahren et al. 1976).
Muscle is the primary site for branched-chain–amino
acid transamination (Goldberg and Chang 1978;
Chuang and Shih 1995). The resulting branched-chain
ketoacids can be either further metabolized there (Gold-
berg and Chang 1978) or transported to liver, kidney,
and heart, where they are oxidized (Chuang and Shih
1995). In the liver, a-isocaproic acid, the product of
leucine transamination, is further metabolized, via 3-
methycrotonyl-CoA and MCC, to acetyl-CoA (fig. 3a),
which can serve as a precursor for ketone-body and is-
oprenoid biosynthesis. In the muscle, leucine can be a
source of energy, via full oxidation to CO2 (Goldberg
and Chang 1978). In agreement with both the predicted
involvement of MCC in the oxidation of leucine in these
tissues and the heteromeric nature of MCC, northern
blot hybridization showed that the MCCA and MCCB
transcripts are coordinately expressed at high levels in
liver, kidney, heart, and skeletal muscle (fig. 3b).MCCA
is transcribed as a single 2.6-kb message; MCCB gives
rise to a minor 2.4-kb transcript and a major 4-kb tran-
script. This long transcript almost certainly results from
further downstream polyadenylation of exon 17, which
would lead to a long (∼1.5 kb) 3′ UTR. The presence of
this long 3′ UTR within the human transcriptome was
confirmed by both RT-PCR (table 1) and the identifi-
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Figure 2 Chromosomal localization of MCCA (A) and MCCB (B). RH-mapping results with the GB4 panel (for MCCA) and with the
G3 and GB4 panels (for MCCB) are shown. The nearly telomeric chromosomal localization of MCCA was confirmed by FISH (see insets of
individual chromosomes, in panel A).
cation of EST clones (GenBank accession numbers
AW439494 and AI869038 [GenBank Overview]) con-
taining this region.
Mutations in MCCA or MCCB, in Patients with MCG
To confirm the involvement of MCCA and MCCB in
MCG, we screened for mutations in the cloned genes in
seven probands. These patients (one fromArgentina, one
from Spain, and five from the United States) were un-
related, although two of them (Gibson et al. 1998) be-
long to the Amish/Mennonite population in Lancaster
County, Pennsylvania. These patients either showed el-
evated excretion of the diagnostic compounds 3-meth-
ylcrotonylglycine or 3-hydroxyisovaleric acid or came to
clinical attention because of their abnormally increased
blood levels of C5-OH. All of them had been shown to
be deficient for MCC but were normal for at least one
of the other biotin-dependent carboxylases (Gibson et
al. 2000) and showed normal [3H]-biotin labeling of PC
and PCCa (see below). These data rule out a multiple-
carboxylase deficiency (i.e., a deficiency of all four bi-
otin-dependent carboxylases) resulting from defects ei-
ther in the insertion of the biotin cofactor into the
apoenzymes or in the recycling of the cofactor (Wolf
1995).
Polyethylene glycol–mediated heterokaryosis between
fibroblast cell lines from five of these patients (fibroblasts
were not available for the remaining two patients) was
used to classify them into two complementation groups
(table 3). By analogy to the deficiency of the dicistronic
enzyme PCC (Gravel et al. 1977; Ugarte et al. 1999),
each of these two complementation groups would be
defined by recessive loss-of-function mutations in one of
the two genes encoding the MCC subunits. Fibroblasts
from the Argentine patient were arbitrarily used as the
reference. Two complementing patients were included
within complementation group A (CGA), and two non-
complementing patients were included, along with the
reference patient, within complementation group B
(CGB) (table 3). In addition, we used [3H]-biotin labeling
of mitochondrial biotin carboxylases, followed by SDS-
PAGE and autoradiography, to resolve PC, MCCa, and
PCCa (Lamhonvah et al. 1983). Fibroblasts of all of
these five patients showed normal PC and PCCa labeling
(data not shown). However, whereas the three CGB pa-
tients showed normal MCCa labeling, one of the two
CGA patients did not (fig. 4), strongly indicating that
CGA is defined by mutations in MCCA.
We detected two missense mutations in MCCA in the
two CGA patients (fig. 5 and table 3). These mutations
were absent in a sample of 100 control chromosomes.
M325R involves a nonconservative substitution leading
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Figure 3 A, Leucine-degradation pathway. The absence of MCC leads to the accumulation of the upstream compounds isovaleryl-CoA
and methylcrotonyl-CoA, which lead to 3-hydroxyisovaleric (3-HIVA) and 3-methylcrotonylglycine (3-MC-Gly), which are biochemical land-
marks of the isolated, biotin-insensitive MCC deficiency. B, Multitissue northern blot hybridization, showing coordinated, high-level expression
of MCCA and MCCB in liver, kidney, heart, and skeletal muscle. b-Actin was used as a loading control. MCCA and MCCB probes were ESTs
“AA605162” and “AI949422,” respectively. Bp brain; Hp heart; SMp skeletal muscle; Cp colon; Tp thymus; Sp spleen; Kp kidney;
Li p liver; Si p small intestine; P p placenta; Lu p lung; PBL p peripheral blood lymphocytes. The human multiple-tissue northern filter
was purchased from Clontech.
to absence of [3H]-biotin MCCa labeling (fig. 4), which
would indicate that it affects either protein stability or
biotinylation. R385S involves a substitution of an ar-
ginine residue that is strictly conserved among humans,
plants, and fungi. Human MCCa Arg385 corresponds
to Arg338 in the biotin-carboxylating component of E.
coli ACC, which appears to form part of a positively
charged pocket for bicarbonate binding (Thoden et al.
2000). This mutation could lead to a kinetic defect with-
out MCCa destabilization, as indicated by the normal
[3H]-biotin labeling of mutant MCCa in fibroblasts of
our patient (table 3). In addition to these mutations, we
detected two frequent polymorphisms in MCCA—the
synonymous point mutation c.396TrC (L132L) and the
missense mutation c.1391ArC (H464P). Proline rather
than histidine is present in the corresponding position
in Arabidopsis MCCa (Song et al. 1994).
We detected three mutations in theMCCB gene in the
three CGB patients (fig. 4 and table 3). An additional
MCCB mutation was found in the two patients who
were not included in complementation studies (table 3
and fig. 5). No mutation was detected in the MCCA
gene of the latter two patients, who, like the three CGB
patients, showed normal MCCa labeling (table 3). Two
of these four MCCB mutations almost certainly repre-
sent null alleles: D172fs (c.516insT) truncates MCCb
after residue 172, and IVS35GrT is a splicing mu-
tation leading to skipping of exon 3, frameshift, and
early truncation (fig. 5). The remaining two mutations
(C167R and A218T) are missense mutations involving
nonconservative substitutions ofMCCb residues that are
strictly conserved among humans, fungi, and plants.
Both mutations are absent from a sample of 100 normal
chromosomes.
In Vivo Involvement of MCC in Leucine Catabolism
The haploid fungus Aspergillus nidulans is able to
grow on a number of amino acids, as the sole carbon
source, using catabolic pathways that are very similar
to those found in humans (Ferna´ndez-Can˜o´n and Pen˜al-
va 1995a). In previous studies, we have exploited this
metabolic versatility and the relatively facile genetic ma-
nipulation of this lower eukaryote in order to charac-
terize the human genes of phenylalanine metabolism
(Ferna´ndez-Can˜o´n and Pen˜alva 1995a, 1995b, 1996,
1998). Aspergillus nidulans grows on leucine and iso-
leucine—and, to a lesser extent, on valine—as the sole
carbon source. dbEST searches allowed us to identify
Aspergillus nidulans mccA and mccB cDNAs, which en-
code fungal MCCa and MCCb, respectively. Their ge-
nomic characterization showed that, together with the
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Figure 4 Results of in vivo [3H]-biotin labeling of mitochondrial
biotin-containing polypeptides PC, PCCa, and MCCa. Cultured fi-
broblasts (relevant genotypes are shown at the top of each lane) were
incubated in the presence of the labeled vitamin and were lysed, and
the protein extracts were loaded onto a 7.5% SDS-polyacrylamide gel.
Labeled proteins were revealed by fluorography.
Table 3
MCCA and MCCB Mutations in Patients with MCG
PATIENT (ORIGIN) GROUP a
MCCa
[3H]-BIOTIN
LABELING?
MUTATION IN b
NUCLEOTIDE CHANGE c PREDICTED CONSEQUENCE(S)MCCA MCCB
15468 (Spain) CGB Yes C167R MCCB c. 499TrC Cys167Arg substitution in MCCb
15469 (Argentina) CGB Yes A218T MCCB c. 652GrA Ala218Thr substitution in MCCb
15626 (United States) … Yes D172fs MCCB c. 517insT MCCb sequence frameshifted after residue 172
15628 (United States) … Yes D172fs MCCB c. 517insT MCCb sequence frameshifted after residue 172
15767 (United States) CGB Yes IVS35rT MCCB c. 2815GrT MCCB exon 3 skipping, frameshift after residue 66
15765 (United States) CGA No M325R MCCA c.974TrG Met325Arg substitution in MCCa
15766 (United States) CGA Yes R385S MCCA c.1155ArC Arg385Ser substitution in MCCa
a An ellipsis (…) denotes that the individual was not classified.
b Found in apparent homozygosis (or in a hemizygosis-like situation; see the text). Missense mutations, which are underlined, were absent
from 100 normal chromosomes.
c Nucleotide numbering referred to the A in the initiation ATG codons of the cDNA sequences in figure 1.
isovaleryl-CoA dehydrogenase gene, these genes are
closely linked within a 14-kb region, in a likely leucine-
degradation cluster (J.M.R. and M.A.P, unpublished
data). We constructed, by homologous recombination,
a null DmccA strain. In contrast to the parental strain,
this DmccA strain is unable to utilize leucine but grows
normally on threonine, isoleucine, or valine (which are
catabolized via propionyl-CoA and PCC) (fig. 6). These
data establish in vivo the specific involvement of MCCa
(and, by extension, MCC) in leucine catabolism.
Discussion
We have characterized, at both the genomic level and
the cDNA level, the human MCCA and MCCB genes
encoding the subunits of MCC, which is an enzyme of
leucine catabolism and which, when deficient, leads to
MCG; and we have detected six MCCA or MCCB mu-
tations in patients diagnosed with the disease. All these
mutations are most likely in homozygosis. However,
since no relatives of the patients were available for seg-
regation analysis, we cannot formally rule out the pos-
sibility that, among the probands, there are compound
heterozygotes carrying a partial or complete deletion of
either the MCCA gene or the MCCB gene.
The six mutations reported here fulfill the criteria for
pathogenic mutations (Cotton and Horaitis 2000): (i)
each of these mutations was detected in a particular
proband after direct sequencing of the complete coding
region of either MCCA or MCCB; (ii) they were con-
firmed in two independent RT-PCR experiments; (iii)
they were confirmed by direct sequencing of genomic
DNA; (iv) they were confirmed by RFLP or SSCP anal-
ysis of the corresponding amplified exons; (v) all six
were absent from a sample of 100 normal chromo-
somes; and (vi) the M325R MCCA missense mutation
leads to absence of biotinylated MCCa, which is a for-
mal proof that this mutation is pathogenic, since the
biotin cofactor is essential for enzyme function (seeWolf
1995); (vii) Arg385, the MCCa residue affected by the
second MCCA missense mutation (R385S), is predicted
to be involved in the binding of one of the enzyme
substrates (see the Results section); (viii) D172fs and
IVS35GrT, two of the four mutations found in
MCCB in homozygosis (or in a hemizygosis-like situ-
ation), result in early protein truncation (table 3) and
almost certainly lead to null alleles; and (ix) the other
two mutations found inMCCB involve nonconservative
substitutions of residues that are strictly conserved
among the three MCCb sequences available (i.e., hu-
man, Arabidopsis, and Aspergillus). We therefore con-
clude that MCG results from loss-of-functionmutations
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Figure 5 Mutations in MCCA and MCCB. A, Mutations in MCCB: results of direct sequencing of PCR-amplified genomic DNA from
controls and from CGB patients who have MCG are shown. Arrows indicate the mutated positions. B, Results of direct sequencing of PCR-
amplified genomic DNA from controls and from CGA patients who have MCG. Arrows indicate the mutated positions. C, IVS35GrTMCCB
mutation, which results in skipping of exon 3. The gel shows the results of agarose-gel electrophoresis and direct sequence analysis of MCCB
cDNA from the region surrounding the exon2/exon3 junction, amplified by RT-PCR with fibroblast mRNA as template, from a control (lane
C) and from the patient (lane P) carrying this mutation. Lane M, molecular-wieght marker.
in either MCCA or MCCB, the genes encoding the a
and b subunits, respectively, of MCC.
The MCCA M325R mutation leading to absence of
biotinylatedMCCa deserves particular attention. In hu-
man PCCa, a polypeptide comprising the carboxyl-ter-
minal 67 amino acids that include the biotin-attachment
sequence Ala-Met-Lys-Met functions as an independent
domain that can be biotinylated in E. coli (Leo´n del Rı´o
and Gravel 1994). Met325, affected by thisMCCAmu-
tation, lies considerably upstream of the corresponding
region in hMCCa (see fig. 1), and therefore the absence
of biotinylated mutant MCCa almost certainly reflects
the absence of the protein, rather than an impairment
of biotinylation. With regard to the efficiency of RT-
PCR amplification, we noticed no differences between
the MCCA transcript from M325R fibroblasts and that
from normal fibroblasts, which would suggest both that
this mutation does not result in mRNA destabilization
and that the absence of MCCa labeling possibly results
from decreased protein stability.
Only two of the probands in the present study carry
the same mutation (D172fs). These individuals are fe-
male adults shown to be deficient forMCCbut clinically
asymptomatic at the moment of diagnosis (Gibson et
al. 1998). They belong to the Amish/Mennonite pop-
ulation and came to clinical attention because their chil-
344 Am. J. Hum. Genet. 68:334–346, 2001
Figure 6 Knockout of the gene for MCCa in Aspergillus nidulans. An Aspergillus nidulans DmccA strain carrying a complete deletion
of the gene encoding fungal MCCa is unable to utilize leucine as the sole carbon source but grows on other branched-chain amino acids. The
parental strain and three independent transformants (denoted “#1”–“#3”) deleted for the mccA gene were grown on synthetic minimal medium
with ammonium chloride as the nitrogen source and with 30 mM of the indicated amino acids as the sole carbon source. Plates were incubated
for 5 d at 37C. Fungi can synthesize carbohydrates from acetyl-CoA, via the glyoxylate cycle—thereby bypassing the Krebs cycle, which leads
to complete oxidation of acetyl-CoA to CO2 and water.
dren, later shown to be normal obligate carriers (Gibson
et al. 1998; present study), showed increased quantities
of 5C-OH in blood, possibly as a result of the accu-
mulation of maternal 5C-OH in the red cells of these
children during pregnancy (Ranieri et al. 2000b). The
absence of symptoms in these Mennonite female adults
is an extreme example of the variable clinical phenotype
of MCG (Sweetman and Williams 1995), in which the
symptoms range frommild muscular weakness to severe
episodes of metabolic decompensation. It is noteworthy
that these two clinically asymptomatic female adults
carry an MCCb null mutation, apparently in homozy-
gosis, and show highly elevated levels of 5C-OH and
3-methylcrotonylglycine, in blood and urine, respec-
tively (Gibson et al. 1998), which is consistent with their
genotype. This shows the significant influence that en-
vironmental factors (such as minor intercurrent infec-
tions or adoption of a protein-rich diet, which fre-
quently trigger metabolic crises) and/or genetic makeup
may have in the clinical outcome of this potentially
severe disease. Therefore, inMCG, as in othermetabolic
monogenic traits, the enzyme-structural gene(s) is the
major determinant of the biochemical phenotype, but
the associated clinical features are complex, somehow
resembling the so-called complex traits (Scriver andWa-
ters 1999).
Although MCG previously had been thought to be a
rare inborn error of metabolism, the introduction of
massive neonatal screening by MS/MS of urine or blood
spots in neonates has revealed that MCG is unexpect-
edly frequent, with an incidence, for example, of ∼1/
27,000 in South Australia (Ranieri et al. 2000a), ∼1/
52,000 in North Carolina (Smith et al. 2000), ∼1/
110,000 in New South Wales (Wilcken et al. 2000), and
∼1/30,000 in Bavaria, where MCG appears to be the
most frequent of the organic acidurias (Roscher et al.
2000). Our work provides the molecular tools to an-
alyze the molecular basis of this emergent disease, paves
the way for future studies on phenotype-genotype cor-
relations, and should facilitate the detection of hetero-
zygote carriers and false positives of neonatal screening.
Finally, this work completes the characterization of all
four biotin-dependent carboxylases of human inter-
mediary metabolism.
Note added in proof.—We have recently learned that
the molecular basis of MCG has also been identified by
Baumgartner et al. (in press).
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